PD-L1 and Immunotherapy in Patients With Non-Small Cell Lung Cancer and Malignant Pleural Effusion

doi 10.33973/pleura3622111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Society of Pleural Diseases

Related search

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

Phase II Study of Ramucirumab and Docetaxel for Previously Treated Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion: Protocol of PLEURAM Study

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated With PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy

Frontiers in Immunology
AllergyImmunology
2017English

P3.04-13 PD-L1-Gene Expression by nCounter Correlates With PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-06 Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks From Pleural Effusion

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells From Patients With Non-Small-Cell Lung Cancer

Cancer Management and Research
Oncology
2020English

FDA Approves Breakthrough Immunotherapy for Patients With Non-Small-Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy